期刊文献+

大剂量重组人红细胞生成素治疗尿毒症贫血的疗效观察 被引量:21

High dose of rhEPO in treatment of uremic anemia
下载PDF
导出
摘要 目的:观察每周1次大剂量皮下注射国产重组人红细胞生成素(rhEPO)治疗尿毒症贫血的临床疗效。方法:20例尿毒症合并肾性贫血的血透患者,随机分为2组,试验组10例,采用国产rhEPO(益比奥,沈阳三生制药公司)10 000 U皮下注射1次/周治疗;对照组1O例,采用进口rhEPO(利血宝,日本麒麟公司)3 000 U皮下注射2~3次/周治疗。治疗期间,监测血常规、血脂、肝肾功能、电解质、血压等指标及患者出现的各种不良反应。结果:试验组显效5例、有效4例、无效1例;对照组显效6例、有效3例、无效1例,治疗前后白细胞、血小板、血脂、肝肾功能、电解质无明显变化。结论:大剂量益比奥每周1次治疗肾性贫血安全可靠、疗效确切,不良反应发生率与利血宝相似,且价格/药效明显低于利血宝。 Objective: To evaluate the clinical effect of high dose of rhEPO on uremic anemia by subcutaneous injection once a week. Methods: Twenty anemic patients on maintenance hemodialysis were divided into 2 groups at random. Ten patients in treatment group accepted 10 000 U of rhEPO (Shenyang Sunshine Pharmaceutical Co. Ltd. ) through subcutaneous injection once a week. Ten patients in control group accepted 3 000 U of EPO (Kirin Kunpeng Bio-pharmaceutical Co. Ltd. ) through subcutaneous injection twice to 3 times a week. Routine blood test,liver and kidney function,electrolyte,blood pressure and side effects were observed. Results: The obvious effective,effective and ineffective cases in treatment group were 5, 4 and 1 respectively and 6,3 and 1 in control group respectively. The pre- and post-treatment liver and kidney function,electrolyte, blood pressure and side effects of the 2 groups had no significant changes. Conclusion: Treatment of uremic anemia with high dose of rhEPO is effective and safe. The side effect of rhEPO is similar in 2 groups. The cost/effect of rhEPO in treatment group is significantly lower than that in control group.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2002年第11期1243-1245,共3页 Academic Journal of Second Military Medical University
基金 上海市卫生系统百名跨世纪优秀学科带头人培养计划(97BR047).
关键词 尿毒症 肾性贫血 重组人红细胞生成素 大剂量 治疗 uremia uremic anemia recombinant human erythropoietin high dose
  • 相关文献

参考文献2

二级参考文献10

  • 1季曙明,黎磊石.应用重组促红细胞生成素治疗长期血透患者贫血[J].中华内科杂志,1993,32(2):100-102. 被引量:6
  • 2郑法雷,毕增祺.小剂量红细胞生成素对透析前慢性肾衰患者贫血的作用[J].中华内科杂志,1993,32(7):440-443. 被引量:8
  • 3Eschbach JW.Correction of the anemia of end-stage renal disease with recombinant human erythropoietin:results of a combinant phase Ⅰand Ⅱclinical trial.New Engl J Med,1987;316:73.
  • 4Casati S.et al.Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having hemodialysis.Br Med J,1987;295:1017.
  • 5US rHu Epo Predialysis Study Group.Double-blind.placebocontrolled study of the therapeutic use of rHu Epo for anemia associated with chromic renal failure in predialysis patients.Am J Kidney Dis,1997;18:50.
  • 6Brown CD.et al.Treatment of azotemic,Nonoliguric.anemic patients with human recombinant erythropoietin raises whole viscosity proportioal to hematocrit.Nephron,1991;59:394.
  • 7Lui SF.et al.Once weekly versus twice weekly subcutaneous administration of recombinant human eryhropoietin in patients on continuous ambulatory peritoneal dialysis.Clin Nephrol,1991;36:246.
  • 8丁小强.应用人基因重组红细胞生成素治疗尿毒症腹透患者贫血[J].中华内科杂志,1993,32:100-100.
  • 9Erslev HJ.Erythropoietin.N Eng J Med 1991;314(29):1339.
  • 10Van wyck DB.Stivelman JC.Ruiz J.et al.iron status in patients receiving erythropoietin for dialysis-associated anemia.Kidney Int 1989;35:712.

共引文献32

同被引文献138

引证文献21

二级引证文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部